Bare Financial Services’s Immunovant IMVT Stock Holding History

Bare Financial Services’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-31	Closed	-$496	–	1435
2025 Q2	$496	Buy	+31	New	+$469	﹤0.01%	1131

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Bare Financial Services's IMVT Position: Q3 2025 in Review

Bare Financial Services sold out of Immunovant (IMVT) in Q3 2025, closing a stake of 31 shares — an estimated $496 sold.

Bare Financial Services first reported a position in IMVT in Q2 2025 and held it in 1 quarter. The position peaked at $496 in Q2 2025. 186 funds tracked by Wall St. Rank hold IMVT as of Q3 2025.

Bare Financial Services reported no remaining Immunovant position as of Q3 2025 after selling out during the quarter.
Bare Financial Services sold 31 Immunovant shares in Q3 2025, an estimated $496.
Bare Financial Services first reported a position in Immunovant in Q2 2025 and held it in 1 quarter.
Bare Financial Services's Immunovant position peaked at $496 in Q2 2025.
186 funds tracked by Wall St. Rank held Immunovant as of Q3 2025.

Based on Bare Financial Services's 13F filing for Q3 2025, filed 12 Nov 2025.